The global Cancer Pain Therapeutics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Opioids, Non-Steroidal Anti-Inflammatory Drugs, Others), By Application (Related Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy).
The Cancer Pain Therapeutics Market focuses on pharmaceuticals and pain management strategies tailored to alleviate cancer-related pain, including neuropathic pain, bone pain, and breakthrough pain associated with tumors and cancer treatments. Therapeutic options in this market include opioid analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), adjuvant medications, and interventional pain procedures aimed at improving pain control, functional status, and quality of life for cancer patients. In 2024, this market addresses personalized pain management approaches, opioid-sparing therapies, and novel analgesic formulations to optimize cancer pain relief and patient comfort.
The global Cancer Pain Therapeutics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Cancer Pain Therapeutics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Cancer Pain Therapeutics Industry include- BioDelivery Science, Daiichi Sankyo, Eli Lilly and Company, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, ProStrakan Group, Teva Pharmaceuticals.
A significant trend in the Cancer Pain Therapeutics market is the shift towards multimodal pain management approaches that combine pharmacological interventions with non-pharmacological modalities to effectively manage cancer-related pain. Traditionally, cancer pain has been managed primarily with opioid analgesics; however, concerns over opioid dependence, tolerance, and adverse effects have prompted healthcare providers to adopt a more comprehensive approach to pain management. Multimodal strategies may include adjuvant medications such as antidepressants, anticonvulsants, and nonsteroidal anti-inflammatory drugs (NSAIDs) to target neuropathic pain, inflammation, and other pain mechanisms. Additionally, non-pharmacological interventions such as physical therapy, acupuncture, cognitive-behavioral therapy, and interventional procedures like nerve blocks and radiofrequency ablation are increasingly integrated into cancer pain management regimens. This trend reflects a holistic approach to addressing the multifactorial nature of cancer pain and improving patients' overall quality of life.
A major driver for the Cancer Pain Therapeutics market is the increasing incidence and prevalence of cancer worldwide, which correlates with a higher demand for effective pain management interventions. Cancer-related pain is a common and distressing symptom experienced by a significant proportion of cancer patients at various stages of their illness. As the burden of cancer continues to rise globally, there is a growing need for safe, efficacious, and accessible pain therapeutics to alleviate suffering and improve patients' comfort and functionality. Additionally, advancements in cancer treatments, including surgery, chemotherapy, radiation therapy, and immunotherapy, have improved survival rates but may also contribute to the development or exacerbation of cancer-related pain. This creates a continuous demand for innovative pain management solutions tailored to the individual needs of cancer patients, driving market growth and innovation in the field of cancer pain therapeutics.
An opportunity for market expansion in the Cancer Pain Therapeutics market lies in the development of targeted and non-opioid analgesic agents that offer effective pain relief with reduced risk of opioid-related adverse effects and dependency. While opioids remain essential for managing moderate to severe cancer pain, there is a growing emphasis on developing alternative analgesic agents with improved safety profiles and mechanisms of action. This includes novel pharmacological targets such as cannabinoid receptors, glutamate receptors, ion channels, and neuroinflammatory pathways implicated in cancer pain. By investing in research and development efforts to discover and validate new drug targets and therapeutic modalities, pharmaceutical companies can address unmet needs in cancer pain management and differentiate their products in a competitive market landscape. Additionally, there is an opportunity to develop personalized pain management approaches based on patients' genetic profiles, pain phenotypes, and treatment preferences, enhancing treatment efficacy and patient satisfaction.
The fastest-growing segment in cancer pain therapeutics is Related Immunotherapy. Immunotherapy, a cutting-edge approach to cancer treatment, harnesses the body's immune system to target and destroy cancer cells. In recent years, immunotherapy has emerged as a promising option for managing cancer-related pain by addressing the underlying mechanisms that contribute to pain and inflammation. Unlike traditional pain medications such as opioids and non-steroidal anti-inflammatory drugs (NSAIDs), which primarily target symptom relief, immunotherapy offers the potential for long-lasting pain control by targeting the immune pathways involved in pain signaling. Additionally, immunotherapy has shown efficacy in enhancing the body's natural pain-relieving mechanisms and reducing the side effects associated with conventional pain medications. With ongoing research and advancements in immunotherapy techniques, the adoption of related immunotherapy for cancer pain management is rapidly increasing, making it the fastest-growing segment in the cancer pain therapeutics market.
By Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
By Application
Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
BioDelivery Science
Daiichi Sankyo
Eli Lilly and Company
Galena Biopharma
Grunenthal Group
GW Pharmaceuticals
Hospira
Johnson & Johnson
ProStrakan Group
Teva Pharmaceuticals
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cancer Pain Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cancer Pain Therapeutics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Cancer Pain Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Cancer Pain Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Cancer Pain Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cancer Pain Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cancer Pain Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cancer Pain Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Cancer Pain Therapeutics Industry
4.2 Key Market Trends in Cancer Pain Therapeutics Industry
4.3 Potential Opportunities in Cancer Pain Therapeutics Industry
4.4 Key Challenges in Cancer Pain Therapeutics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Cancer Pain Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Cancer Pain Therapeutics Market Outlook by Segments
7.1 Cancer Pain Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
By Application
Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
8 North America Cancer Pain Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Cancer Pain Therapeutics Markets in 2024
8.2 North America Cancer Pain Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cancer Pain Therapeutics Market size Outlook by Segments, 2021-2030
By Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
By Application
Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
9 Europe Cancer Pain Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Cancer Pain Therapeutics Markets in 2024
9.2 Europe Cancer Pain Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cancer Pain Therapeutics Market Size Outlook by Segments, 2021-2030
By Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
By Application
Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
10 Asia Pacific Cancer Pain Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Cancer Pain Therapeutics Markets in 2024
10.2 Asia Pacific Cancer Pain Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cancer Pain Therapeutics Market size Outlook by Segments, 2021-2030
By Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
By Application
Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
11 South America Cancer Pain Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Cancer Pain Therapeutics Markets in 2024
11.2 South America Cancer Pain Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cancer Pain Therapeutics Market size Outlook by Segments, 2021-2030
By Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
By Application
Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
12 Middle East and Africa Cancer Pain Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Cancer Pain Therapeutics Markets in 2024
12.2 Middle East and Africa Cancer Pain Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cancer Pain Therapeutics Market size Outlook by Segments, 2021-2030
By Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
By Application
Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
BioDelivery Science
Daiichi Sankyo
Eli Lilly and Company
Galena Biopharma
Grunenthal Group
GW Pharmaceuticals
Hospira
Johnson & Johnson
ProStrakan Group
Teva Pharmaceuticals
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Type
Opioids
Non-Steroidal Anti-Inflammatory Drugs
Others
By Application
Related Immunotherapy
Radiotherapy
Chemotherapy
Hormone Therapy
The global Cancer Pain Therapeutics Market is one of the lucrative growth markets, poised to register a 5.8% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
BioDelivery Science, Daiichi Sankyo, Eli Lilly and Company, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, ProStrakan Group, Teva Pharmaceuticals
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume